Suppr超能文献

[全球糖尿病的直接和间接成本]

[Direct and indirect diabetes costs in the world].

作者信息

Logminiene Zeneta, Norkus Antanas, Valius Leonas

机构信息

Clinic of Family Medicine, Kaunas University of Medicine, Eiveniu 2, 3007 Kaunas, Lithuania.

出版信息

Medicina (Kaunas). 2004;40(1):16-26.

Abstract

Diabetes is becoming one of the major public health problems because a great proportion of the healthcare expenditure has been spent on the treatment of its associated morbidity and mortality. Diabetes is also a major cause of premature mortality, stroke, cardiovascular disease, peripheral vascular disease, congenital malformations as well as long- and short-term disability. In addition, persons with diabetic complications have a lower quality of life compared with persons without diabetes. The goal of this paper is to review the studies on the costs of diabetes, to identify the strengths and limitations of currently available diabetes cost studies, and to identify future research areas that will help us to better understand the economic burden of diabetes. The economic burden of diabetes mellitus is enormous in the world. Cost or illness estimates are often cited as an important element in the choices made regarding diabetes care and management. Studying these economic aspects presents several challenges, such as collecting the appropriate epidemiological and cost data, determining the diabetes attributable factors for premature morbidity and mortality, and determining methods to account for premature morality, disability, and reduced quality of life. The cost to care for diabetes puts a tremendous burden on both the patient and the payer. The direct cost of diabetes increased from 1.7 billion US dollars in 1969 to 44.4 billion US dollars in 1997. Several studies over the years have found that indirect costs related to diabetes are higher than direct. Indirect costs during 28 years increased 33 times, from 1.6 billion US dollars in 1969 to 54.1 billion US dollars in 1997. The expenses of one diabetic patient highly vary in different countries: from 13 US dollars in Bangladesh to 11,157 US dollars in USA per one year. Most of diabetes expenditure is used to pay for inpatient services (60-85%); the biggest part of it is incurred because of late diabetes complications (70%). Diabetes accounted to 3-12% of total healthcare expenditure in different countries. In this era of limited resources and escalating costs, it is critical to have an understanding of the economics of diabetes in order to develop and implement sound public health and prevention policies.

摘要

糖尿病正成为主要的公共卫生问题之一,因为很大一部分医疗保健支出都用于治疗其相关的发病和死亡情况。糖尿病也是过早死亡、中风、心血管疾病、外周血管疾病、先天性畸形以及长期和短期残疾的主要原因。此外,与没有糖尿病的人相比,糖尿病并发症患者的生活质量较低。本文的目的是回顾关于糖尿病成本的研究,确定当前可用的糖尿病成本研究的优势和局限性,并确定有助于我们更好地理解糖尿病经济负担的未来研究领域。糖尿病的经济负担在全球范围内是巨大的。成本或疾病估计常常被视为糖尿病护理和管理决策中的一个重要因素。研究这些经济方面存在若干挑战,例如收集适当的流行病学和成本数据、确定糖尿病导致过早发病和死亡的因素,以及确定考虑过早死亡、残疾和生活质量下降的方法。糖尿病护理成本给患者和支付方都带来了巨大负担。糖尿病的直接成本从1969年的17亿美元增加到1997年的444亿美元。多年来的几项研究发现,与糖尿病相关的间接成本高于直接成本。28年间间接成本增加了33倍,从1969年的16亿美元增加到1997年的541亿美元。一名糖尿病患者的费用在不同国家差异很大:从孟加拉国的每年13美元到美国的每年11,157美元。糖尿病支出的大部分用于支付住院服务费用(60 - 85%);其中最大一部分是由于糖尿病晚期并发症(70%)产生的。在不同国家,糖尿病占医疗保健总支出的3 - 12%。在资源有限且成本不断上升的这个时代,了解糖尿病经济学对于制定和实施合理的公共卫生及预防政策至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验